News

Docetaxel as a vital option for corticosteroid-refractory prostate cancer

Docetaxel as a vital option for corticosteroid-refractory prostate cancer

The efficacy of docetaxel (TAX) chemotherapy for corticosteroid-refractory refractory prostate cancer (CRPC) is uncertain. H. Kume and colleagues conducted a study to investigate docetaxel as an option in treating corticosteroid-refractory prostate cancer. They published their findings in an online...
Late Breaking News: A preview

Late Breaking News: A preview

One of the final sessions of the congress will host three speakers presenting the very latest developments in their research. The Late Breaking News presentations, part of the fourth plenary session, will provide real “scoops” for attending urologists. All...
EAU awards mark high quality urology research in Europe and beyond

EAU awards mark high quality urology research in Europe and beyond

More than twenty awards for excellence in urology research were handed out during the 25th Anniversary EAU Congress, marking outstanding achievements presented at the meeting. “What makes the EAU Congress a success is the quality of its scientific contents,”...